Figure 1From: Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancerPharmakinetics. Individual (open circles) and geometric mean (horizontal line) telatinib Cmax and AUC(0-12) on day 14 of cycle 1. Geometric mean for the combined 1200 mg plus 1500 mg dose levels is shown with 1500 mg data.Back to article page